New York, Jan 10, 2026, 03:42 EST — Market closed
- GSK ADRs closed Friday up 0.3% at $50.39; London shares slipped 0.26% to 1,886 pence
- AnaptysBio moved to dismiss part of a claim in a royalty dispute tied to GSK cancer drug Jemperli
- Investors next look to Jan 13 (J.P. Morgan healthcare conference) and Feb 4 (full-year results)
AnaptysBio said it filed a motion asking a U.S. court to dismiss part of a claim by GSK plc’s oncology unit, escalating a dispute over royalties tied to sales of cancer drug Jemperli, a PD-1 inhibitor — a kind of immunotherapy that helps the immune system attack tumours. Tesaro sued AnaptysBio in Delaware in November seeking to terminate a 2014 licence and halve royalty and milestone payments, while AnaptysBio countersued and pointed to trials involving rival PD-1 drugs including Merck’s Keytruda; the case is set for a July 14–17 trial and the court is expected to hear the motion by early March, with royalties under the licence rising to 25% on annual sales above $2.5 billion through patents expiring in 2035-36. GSK did not immediately respond to a request for comment, and its U.S.-listed shares ended Friday up 0.3% at $50.39.
Why it matters now: the dispute sits on top of a commercial oncology product in a class where competition is brutal, pricing is watched, and partners fight over the split when a drug starts to matter. Separately, Noetik said it signed a five-year, non-exclusive licensing deal giving GSK access to its cancer research “foundation models” — large AI models trained on biological datasets — with $50 million in upfront and near-term milestone payments and annual licensing fees on top; GSK executive Kim Branson called Noetik’s approach to generating spatial data at scale “novel”. Business Wire
Investors get another checkpoint soon. GSK’s calendar shows management is due at the J.P. Morgan Healthcare Conference on Jan. 13 and the company will publish full-year and fourth-quarter results on Feb. 4 — dates that could draw questions on litigation exposure, oncology priorities and how hard it leans into partnerships like Noetik.
In London, GSK shares ended Friday down 0.26% at 1,886 pence, after trading between 1,871 and 1,896, according to historical pricing data. The stock is near its 52-week high of 1,909.5 pence, with the low at 1,242.5.
But there’s a simple risk: courts do what they do, and timelines slip. If Tesaro convinces the judge it can reset or end the licence terms, the royalty stream shifts; if AnaptysBio lands its claims, GSK could face a longer, noisier fight around how it backs Jemperli against bigger PD-1 rivals.
Next is the expected early-March hearing on the motion, and then GSK’s Feb. 4 results — the nearer-term catalyst likely to set the tone for GSK stock into the next session and beyond.
